This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
HGEN.Q Aperçu des actions
A clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response.
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 1/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
+ 2 plus de risques
Humanigen, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$0.000001 |
| Plus haut sur 52 semaines | US$0.21 |
| Plus bas sur 52 semaines | US$0.000001 |
| Bêta | -1.34 |
| 1Variation sur 1 mois | 0% |
| Variation sur 3 mois | 0% |
| Variation sur 1 an | -100.00% |
| 3Variation sur 3 ans | -100.00% |
| Variation sur 5 ans | -100.00% |
| Évolution depuis l'introduction en bourse | -100.00% |
Nouvelles et mises à jour récentes
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04
Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29Rendement pour les actionnaires
| HGEN.Q | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -99.5% | 0.6% | 0.8% |
| 1Y | -100.0% | 27.4% | 38.3% |
Rendement vs Industrie: HGEN.Q underperformed the US Biotechs industry which returned 14% over the past year.
Rendement vs marché: HGEN.Q underperformed the US Market which returned 22% over the past year.
Volatilité des prix
| HGEN.Q volatility | |
|---|---|
| HGEN.Q Average Weekly Movement | 102,515.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Cours de l'action stable: HGEN.Q's share price has been volatile over the past 3 months.
Volatilité au fil du temps: HGEN.Q's weekly volatility has increased from 50618% to 102515% over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2000 | 6 | Cameron Durrant | www.humanigen.com |
Humanigen, Inc. Résumé des fondamentaux
| HGEN.Q statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$119.00 |
| Bénéfices(TTM) | -US$53.63m |
| Recettes(TTM) | US$1.70m |
0.0x
Ratio P/S0.0x
Ratio P/ELe site HGEN.Q est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| HGEN.Q compte de résultat (TTM) | |
|---|---|
| Recettes | US$1.70m |
| Coût des recettes | US$38.73m |
| Marge brute | -US$37.03m |
| Autres dépenses | US$16.61m |
| Les revenus | -US$53.63m |
Derniers bénéfices déclarés
Mar 31, 2023
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.45 |
| Marge brute | -2,179.40% |
| Marge bénéficiaire nette | -3,156.80% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de HGEN.Q?
Voir les performances historiques et les comparaisons